Moses Makunje
Fortune : 325 695 $ au 31/05/2026
Fortune : 325 695 $ au 31/05/2026
Moses Makunje is currently VP-Finance & Principal Accounting Officer at Nuvation Bio, Inc. since 2020.
Formerly, Mr. Makunje was Controller at Adverum Biotechnologies, Inc. from 2017 to 2019 and Controller at Maze Therapeutics, Inc. from 2019 to 2020.
Mr. Makunje completed undergraduate and MBA degrees at Golden Gate University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/02/2026 | 68 137 ( 0,02 % ) | 325 695 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| NUVATION BIO INC. | Comptroller/Controller/Auditor | 27/11/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Comptroller/Controller/Auditor | 01/07/2020 |
| ADVERUM BIOTECHNOLOGIES, INC. | Comptroller/Controller/Auditor | 01/03/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Golden Gate University
Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells novel gene therapies | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national